Prediction of blood-brain barrier permeation of α-adrenergic and imidazoline receptor ligands using PAMPA technique and quantitative-structure permeability relationship analysis

European Journal of Pharmaceutical Sciences

Volumn 68, Issue , 2015, Pages 94-105

  Vucicevic, Jelica ^a   Nikolic, Katarina ^a   Dobričić, Vladimir ^a   Agbaba, Danica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Blood brain barrier permeability; Imidazoline ligands; PAMPA; QSPR

Indexed keywords

AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; AMILORIDE; BRIMONIDINE; CITALOPRAM; CLONIDINE; EFAROXAN; FLUOXETINE; GUANABENZ; GUANFACINE; HARMAN; HARMINE; IDAZOXAN; IMIDAZOLINE RECEPTOR; LAMOTRIGINE; LEVOMEPROMAZINE; LIGAND; LORAZEPAM; MIANSERIN; MOXONIDINE; NAPHAZOLINE; OXAZEPAM; OXYMETAZOLINE; RILMENIDINE; SERTRALINE; TIZANIDINE; TRAMAZOLINE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE; ALPHA ADRENERGIC RECEPTOR; ARTIFICIAL MEMBRANE; DRUG; LIPID;

ARTICLE; ARTIFICIAL NEURAL NETWORK; ASSAY; BLOOD BRAIN BARRIER; DENSITY FUNCTIONAL THEORY; DRUG PENETRATION; HYDROGEN BOND; MULTIPLE LINEAR REGRESSION ANALYSIS; NONHUMAN; PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY ASSAY; PH; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; ARTIFICIAL MEMBRANE; BIOLOGICAL MODEL; CELL MEMBRANE PERMEABILITY; CHEMISTRY; METABOLISM; PERMEABILITY;

BLOOD-BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; IMIDAZOLINE RECEPTORS; LIGANDS; LIPIDS; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, ADRENERGIC, ALPHA;

EID: 84920773866     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.12.014     Document Type: Article

References (58)

1. N.J. Abbott Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models Drug Discov. Today Technol. 1 2004 407 416
2. N.J. Abbott, L. Rönnbäck, and E. Hansson Astrocyte-endothelial interactions at the blood-brain barrier Nat. Rev. Neurosci. 7 2006 41 53
3. APPENDIX D. 2008. Descriptor (Optional)-Cadaster.< www.cadaster.eu/sites/cadaster.eu/files/challenge/Descriptors-400.pdf >.
4. A. Avdeef Absorption and Drug Development 2003 John Wiley & Sons Inc. Hoboken, New Jersey
5. A. Avdeef The rise of PAMPA Expert Opin. Drug Metab. Toxicol. 1 2005 325 342
6. A. Avdeef, M. Strafford, E. Block, M. Balogh, W. Chambliss, and I. Khan Drug absorption in vitro model: filter-immobilized artificial membranes. Studies of the permeability properties of lactones in Piper methysticum Forst Eur. J. Pharm. Sci. 14 2001 271 280
7. A.D. Becke Density-functional thermochemistry. III. The role of exact exchange J. Chem. Phys. 98 1993 5648 5652
8. P. Bousquet, J. Feldman, and J. Schwartz Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines J. Pharmacol. Exp. Ther. 230 1984 232 236
9. P. Bousquet, G. Bricca, M. Dontenwill, J. Feldman, H. Greney, A. Belcourt, J. Stutzmann, and E. Tibiriça From the α2-adrenoceptors to the imidazoline preferring receptors Fundam. Clin. Pharmacol. 6 Suppl. 1 1992 15S 21S
10. CambridgeSoft Corporation. 2013. ChemBio3D Ultra, Version 13.0. Cambridge, MA, USA.
11. 2-adrenoreceptors in the rostral ventrolateral medulla to sympathetic baroreflex inhibition by systemic rilmenidine J. Hypertens. 25 2007 147 155
12. ChemAxon. 2013. MarvinSketch 6.1.0. Budapest, Hungary.
13. D.E. Clark In silico prediction of blood-brain barrier permeation Drug Discov. Today 8 2003 927 933
14. 2 parameter for QSAR validation J. Chem. Inform. Mod. 49 2009 1669 1678
15. L. Di, E.H. Kerns, K. Fan, O.J. McConnell, and G.T. Carter High throughput artificial membrane permeability assay or blood-brain barrier Eur. J. Med. Chem. 38 2003 223 232
16. P.R. Duchowicz, M. Fernandez, J. Caballero, E.A. Castro, and F.M. Fernandez QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase Bioorg. Med. Chem. 14 2006 5876 5889
17. G.F. Ecker, and C.R. Noe In silico prediction models for blood-brain barrier permeation Curr. Med. Chem. 11 2004 1617 1628
18. R.M. Eglen, A.L. Hudson, D.A. Kendall, D.J. Nutt, N.G. Morgan, V.G. Wilson, and M.P. Dillon 'Seeing through a glass darkly': casting light on imidazoline 'I' sites Trends. Pharmacol. Sci. 19 1988 381 390
19. L. Eriksson, E. Johansson, N. Kettaneh-Wold, J. Trygg, C. Wikström, and S. Wold Multi-and Megavariate Data Analysis. Basic Principles and Applications I second ed. 2001 Umetrics Academy Umeå, Sweden
20. P. Ernsberger, R. Giuliano, R.N. Willette, and D.J. Reis Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla J. Pharmacol. Exp. Ther. 253 1990 408 418
21. S. Filipic, K. Nikolic, I. Vovk, M. Krizman, and D. Agbaba Quantitative structure-mobility relationship analysis of imidazoline receptor ligands in CDs-mediated CE Electrophoresis 34 2013 471 482
22. P. Garberg, M. Ball, N. Borg, R. Cecchelli, L. Fenart, R.D. Hurst, T. Lindmark, A. Mabondzo, J.E. Nilsson, T.J. Raub, D. Stanimirovic, T. Terasaki, J.O. Oberg, and T. Osterberg In vitro models for the blood-brain barrier Toxicol. In Vitro 19 2005 299 334
23. M. Gumbleton, and K.L. Audus Progress and limitation in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier J. Pharm. Sci. 90 2001 1681 1698
24. T. Hancock, R. Put, D. Coomans, Y.V. Heyden, and Y. Everingham A performance comparison of modern statistical techniques for molecular descriptor selection and retention prediction in chromatographic QSPR studies Chemometr. Intell. Lab. 76 2005 185 196
25. G.A. Head, and D.N. Mayorov Imidazoline receptors, novel agents and therapeutic potential Cardiovasc. Hematol. Agents. Med. Chem. 4 2006 17 32
26. S.A. Hitchcock, and L.D. Pennington Structure-brain exposure relationships J. Med. Chem. 49 2006 7559 7583
27. R.P. Iczkowski, and J.L. Margrave Electronegativity J. Am. Chem. Soc. 83 1961 3547 3551
28. M. Jalali-Heravi, Y. Shen, M. Hassanisadi, and M.G. Khaledi Prediction of electrophoretic mobilities of peptides in capillary zone electrophoresis by quantitative structure-mobility relationships using the Offord model and artificial neural networks Electrophoresis 26 2005 1874 1885
29. M. Kansy, F. Senner, and K. Gubernator Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes J. Med. Chem. 41 1998 1007 1010
30. A. Kimura, R.J. Tyacke, J.J. Robinson, S.M. Husbands, M.C. Minchin, D.J. Nutt, and A.L. Hudson Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site Brain Res. 1279 2009 21 28
31. H. Kirchherr, and W.N. Kühn-Velten Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach J. Chromatogr. B 843 2006 100 113
32. P. Labute A widely applicable set of descriptors J. Mol. Graph. Model. 18 2000 464 477
33. C. Lee, W. Yang, and R.G. Parr Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density Phys. Rev. B 37 1988 785 789
34. G.R. Marshall Binding-site modeling of unknown receptors H. Kubinyi, 3D QSAR in Drug Design - Theory, Methods and Applications 1994 ESCOM Leiden 80 116
35. J. Mensch, L. Jaroskova, W. Sanderson, A. Melis, C. Mackie, G. Verreck, M.E. Brewster, and P. Augustijns Application of PAMPA-models to predict BBB permeability including efflux ratio, plasma protein binding and physicochemical parameters Int. J. Pharm. 395 2010 182 197
36. P.A.P. Moran Notes on continuous stochastic phenomena Biometrika 37 1950 17 23
37. N.G. Morgan, and S.L. Chan Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Curr. Pharm. Des. 7 2001 1413 1431
38. I. Moriguchi, S. Hirono, Q. Liu, I. Nakagome, and Y. Matsushita Simple method of calculating octanol/water partition coefficient Chem. Pharm. Bull. 40 1992 127 130
39. P.K. Ojha, and K. Roy Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection Chemometr. Intell. Lab. 109 2011 146 161
40. R.G. Parr, and W. Yang Density-Functional Theory of Atoms and Molecules 1989 Oxford University Press New York
41. A. Reichel, and D.J. Begley Potential of immobilized artificial membranes for predicting drug penetration across the blood-brain barrier Pharm. Res. 15 1998 1270 1274
42. Schuur, J., Gasteiger, J., 1996. Software Development in Chemistry -Vol. 10(Gasteiger, J., ed.), Fachgruppe Chemie-Information-Computer (CIC), Frankfurt am, Main.
43. J.H. Schuur, P. Selzer, and J.J. Gasteiger The coding of the three-dimensional structure of molecules by molecular transforms and its application to structure-spectra correlations and studies of biological activity Chem. Inf. Comput. Sci. 36 1996 334 344
44. Simulation Plus Inc, 2013. ADMET Predictor 6.5.0013. Lancaster, CA.
45. S.N. Sivanandam, and M. Paulraj Introduction to Artificial Neural Networks 2009 Vikas New Delhi
46. G.W. Snedecor, and W.G. Cochran Statistical Methods 1967 Oxford & IBH New Delhi
47. StatSoft Inc., 1998. STATISTICA Neural Networks 4.0. Tulsa, OK, USA.
48. TALETE srl. 2010. Dragon 6.0. Milano, Italy.
49. TALETE srl. 2013. Molecular Descriptors, QSAR, Chemometrics and Chemoinformatics-Dragon Molecular Descriptor List. < www.talete.mi.it/products/dragon-molecular-descriptor-list.pdf >.
50. T. Terasaki, S. Ohtsuki, S. Hori, H. Takanaga, E. Nakashima, and K. Hosoya New approaches to in vitro models of blood-brain barrier drug transport Drug Discov. Today 8 2003 944 954
51. F. Tesson, I. Limon-Boulez, P. Urban, M. Puype, J. Vandekerckhove, I. Coupry, D. Pompon, and A. Parini Localization of I2-imidazoline binding sites on monoamine oxidases J. Biol. Chem. 270 1995 9856 9861
52. E. Tibirica, J. Feldman, and P. Bousquet Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anesthetized rats J. Pharmacol. Exp. Ther. 244 1988 1062 1066
53. R. Todeschini, and V. Connsoni Handbook of Molecular Descriptors 2000 WILEY-VCH Weinheim
54. A. Tropsha Best practices for QSAR model development, validation and exploitation Mol. Inform. 29 2010 476 488
55. Umetrics AB. 2008. SIMCA P+ Program, Version 12.0.0.0. Umea, Sweden.
56. V.N. Viswanadhan, M.R. Reddy, R.J. Bacquet, and M.D. Erion Assessment of methods used for predicting lipophilicity: application to nucleosides and nucleoside bases J. Comput. Chem. 14 1993 1019 1026
57. K. Vucicevic, G. Popovic, K. Nikolic, I. Vovk, and D. Agbaba An experimental design approach to selecting the optimum HPLC conditions for the determination of 2-arylimidazoline derivatives J. Liq. Chromatogr. R. T. 32 2009 656 667
58. C.H. Yoon, S.J. Kim, B.S. Shin, K.C. Lee, and S.D. Yoo Rapid screening of blood-brain penetration of drugs using the immobilized artificial membrane phosphatidylcholine column chromatography J. Biomol. Screen. 11 2006 13 20